🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

'Patient & public involvement & engagement in statistical methodology'. New paper in RSS Significance academic.oup.com/jrssig/article… paywall applies £££

An exceptional new NEJM review on cancer of unknown origin nejm.org/doi/full/10.10…

“We must focus on where the answers are – the lived experience of patients.” HSE Ireland CEO Bernard Gloster speaking openly & honestly at #FHsummit25 on challenges, access, quality & safety of care, capacity, progress, innovation, tech, better outcomes & how it all comes together.

📢 The Cancer Trials Ireland team is on its way to ASCO 2025! 🌎 📍 Will you be in Chicago? Let’s meet up to discuss opportunities - you can book a meeting with our team Seamus O’Reilly MD PhD , Angela Clayton-Lea and Olivia McLoughlin) by following the link: bit.ly/3Z71TiV

For lovers of Shetland and in preparation for the new Jimmy Perez, The Killing Stones, out this autumn, White Nights is a June Kindle deal and available all month for only 99p

Good opportunity to address #FutureHealthSummit today Future Health Summit 2025 setting out and building on yesterday’s priorities delivered by Jennifer Carroll MacNeill TD Department of Health HSE Ireland Delighted to acknowledge two award recipients in cancer.

The Health Minister welcomed the Project and said pursuing digitally innovative approaches "holds real promise for both service providers and those needing timely access to health and social care".

Women’s health issues remain underreported, underrepresented, and under-prioritised—despite making up half the global population. 🎥 In a new video, experts and Lancet Editors advocate for equitable healthcare to transform women’s health: tinyurl.com/22fkf865

👏👏👏Superb presentation by Drs Abdou, Trapani, Zerdes & Rozenblit Breast International Group National Cancer Institute NCTN mtg funded by The Breast Cancer Research Foundation Eloquent outline of how we can help them impact patient care 👇

Just in time for #ASCO25 ASCO "The #evidence is becoming irrefutable and catalyzing a call for #universal #germline #genetictesting for all #patients with any #cancer type for the purposes of getting those #patients on the right #therapies." "All #patients with #cancer should

HSE cauda equina guideline ‘unworkable’ without wider MRI access IAEM Trauma and Orthopaedic Programme Dr Colm Henry, CCO HSE Ireland RCSI National Patient Safety Office Spinal Injuries IRL #caudaequina #MRI #CES medicalindependent.ie/in-the-news/ne…

Unique opportunity to be part of shaping clinical guidelines and ensuring quality of patent care HIQA If this sounds of interest visit tinyurl.com/bdh22kfp The first panel meeting will take place in early July.

We are absolutely thrilled to officially launch “Menopause, Diet and Cancer”. Shaped by the voices of 16 women who helped design what they needed most – Menopause, Diet and Cancer is not a clinical manual; it’s a book designed to be part of your everyday life—and your kitchen

We are delighted to announce that Angela Clayton-Lea has been appointed as the new CEO of CancerTrialsIreland 🌈! (effective June 9th) Follow her here: Angela Clayton-Lea. Angela is attending ASCO for the next few days - if you are there too, reach / book a meeting with Angela & the

Today’s the day!!!! Come join us!!! #ASCO25

🚨 BREAKING NEWS 🚨 📉 New research shows #SGLT2inhibitors slash heart failure risk by up to 99% in #BreastCancer patients receiving cardiotoxic treatments, potentially saving thousands of lives. #Chemotherapy saves lives, but often damages the heart. Now, a drug already widely

Is liquid biopsy useful in bone-only metastatic #breastcancer? Surprise! ✅Pts w bone-only disease are just as likely to have detectable ctDNA ✅ctDNA tumor fraction remains prognostic in bone-only setting link.springer.com/article/10.100… Foundation Medicine The James Ohio State Medical Oncology

Tough news on HER3-DXd. But negative trials don't always mean failed drugs. As a patient and advocate, I understand why (toxicities, lack of OS - they matter). But, I also find myself asking, why DID it work for the people it helped? What about trial design? Prior treatment(s)?

Interesting results from a 1L trial of ET+ribo+ trastuzumab for HR+/HER2+ MBC (n=90). ORR 61%, mPFS 30 months. Confirming what we’re realizing more and more: patients with triple-positive metastatic disease NEED to receive a CDK4/6 inhibitor at part of their 1L treatment. #ASCO25

In 2022, Janice Cowden , Dear Dr. Researcher, PhD, & I sat together to hear the much anticipated DESTINY-Breast 04 trial results. As cancer survivors, when we see data, we see the patients behind the data, we ARE the patients behind the data, & we’re grateful to still be here! #ASCO25